John Renger has sold CERE and made no open-market buys since Nov 2021

Insider Type: Person

Dr. John J. Renger is a neuroscientist and pharmaceutical executive who served as Chief Scientific Officer at Cerevel Therapeutics Holdings, Inc., where he led the company’s research initiatives and early clinical development strategy for its neuroscience pipeline.( He joined Cerevel in 2019 from Imbrium Therapeutics L.P., where he was Vice President of Research and Development and Regulatory Affairs, directing overall scientific strategy and clinical development programs.( Over nearly two decades in industry, including a 15-year tenure at Merck & Co. culminating as Associate Vice President leading therapeutic target acceleration and translational capabilities for neuroscience programs, he has overseen teams that advanced more than 40 compounds into clinical development for nervous system disorders such as pain, neurodegenerative diseases, ADHD, essential tremor, schizophrenia, and chronic insomnia.(

Renger is Principal Owner of Neurtuitive LLC, a role he has held since 2022, and has served on multiple boards and scientific advisory boards, including Libra Therapeutics’ Scientific Advisory Board.( A neuroscientist by training, he completed his B.S. in biology and Ph.D. in biological sciences and neurogenetics at the University of Iowa, followed by postdoctoral work at the Massachusetts Institute of Technology Center for Learning and Memory and prior research at Japan’s RIKEN Brain Science Institute.( He has authored more than 140 peer‑reviewed publications and is frequently cited in both scientific literature and the popular press for his contributions to neuroscience drug discovery and development.(

Written by Perplexity from public sources.